Wall Street analysts expect Crispr Therapeutics AG (NASDAQ:CRSP) to report earnings of $0.04 per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Crispr Therapeutics’ earnings, with the lowest EPS estimate coming in at $0.01 and the highest estimate coming in at $0.07. Crispr Therapeutics reported earnings of ($0.92) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 104.3%. The firm is expected to issue its next quarterly earnings report on Monday, February 24th.

According to Zacks, analysts expect that Crispr Therapeutics will report full-year earnings of $0.65 per share for the current year, with EPS estimates ranging from $0.59 to $0.71. For the next fiscal year, analysts expect that the firm will report earnings of ($4.64) per share, with EPS estimates ranging from ($5.38) to ($3.67). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million.

CRSP has been the topic of a number of recent analyst reports. Piper Jaffray Companies restated a “buy” rating and set a $104.00 price target on shares of Crispr Therapeutics in a report on Monday, December 16th. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a report on Friday, December 6th. BidaskClub lowered shares of Crispr Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, December 13th. ValuEngine raised shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 price objective on shares of Crispr Therapeutics in a research report on Monday, December 23rd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $71.38.

Shares of CRSP stock traded down $0.74 during trading hours on Tuesday, reaching $66.01. 999,939 shares of the stock traded hands, compared to its average volume of 985,513. Crispr Therapeutics has a 1-year low of $26.00 and a 1-year high of $74.00. The business has a fifty day moving average price of $64.60 and a 200 day moving average price of $50.48. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $3.68 billion, a PE ratio of -19.19 and a beta of 3.31.

In related news, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total transaction of $412,500.00. Following the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at $412,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock worth $3,620,760 over the last ninety days. 21.40% of the stock is currently owned by insiders.

A number of hedge funds have recently bought and sold shares of CRSP. Nikko Asset Management Americas Inc. grew its position in Crispr Therapeutics by 48.4% in the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after acquiring an additional 906,006 shares in the last quarter. Orbimed Advisors LLC bought a new stake in Crispr Therapeutics in the third quarter worth approximately $21,167,000. Price T Rowe Associates Inc. MD grew its position in Crispr Therapeutics by 19.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after acquiring an additional 121,176 shares in the last quarter. Wells Fargo & Company MN grew its position in Crispr Therapeutics by 23.9% in the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after acquiring an additional 116,540 shares in the last quarter. Finally, Balyasny Asset Management LLC bought a new stake in Crispr Therapeutics in the second quarter worth approximately $5,165,000. 49.82% of the stock is owned by institutional investors.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

See Also: Straddles

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link